Predict your next investment

Corporation
HEALTHCARE | Drug Development
ucb-group.com

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

About Oxford Glycosciences

was a technology developer in the fields of glycobiology and proteomics. Utilizing its technology, the company developed a lead pharmaceutical product Zavesca, that was approved by the European Commission, and established proteomics collaborations with several multi-national pharmaceutical companies.

Oxford Glycosciences Headquarter Location

1950 Lake Park Drive

Smyrna, Georgia, 30080,

United States

Latest Oxford Glycosciences News

Celltech Group PLC (“CELLTECH”) Cash Offer for Oxford Glycosciences PLC (“OGS”)

Jan 30, 2015

Source NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA OR JAPAN Celltech Group  Plc ("Celltech") Cash Offer For Oxford Glycosciences Plc ("OGS") April 11, 2003 -- Celltech is pleased to note the announcement earlier today that the Board of OGS now recommends that OGS Shareholders accept Celltech’s all cash offer of 182 pence per share. Celltech also announces that it has today purchased a further 20,525,985 OGS Shares at a price of 182 pence per share, representing approximately 36.65 per cent. of the issued share capital of OGS. As announced on 24 March 2003, Celltech has previously purchased 5,892,971 OGS Shares representing approximately 10.52 per cent of the issued share capital of OGS and, as at 3.00pm (London time) today, valid acceptances of its Offer had been received in respect of 1,421,210 OGS Shares (including those represented by OGS ADSs), representing approximately 2.54 per cent. of the issued share capital of OGS. Accordingly, and subject to settlement of today's purchases, an aggregate of 27,840,166 OGS Shares (including those represented by OGS ADSs), representing approximately 49.71 per cent. of the issued share capital of OGS, have been acquired by Celltech or validly assented to its Offer. As a result of today's purchases, Celltech's Offer of 182 pence in cash for each OGS Share is now conditional only on Celltech having received acceptances in respect of OGS Shares which, together with OGS Shares acquired or agreed to be acquired, will result in Celltech (and any person acting in concert with Celltech) holding OGS Shares carrying more than 50 per cent. of the voting rights in OGS. Save as set out above, neither Celltech, nor any person acting or deemed to be acting in concert with Celltech, owned any OGS Shares on 22 January 2003 (being the business day prior to the commencement of the offer period), nor have any of such persons acquired or agreed to acquire any OGS Shares (including OGS Shares represented by OGS ADSs) during the offer period and no acceptances of the Offer have been received from any persons acting or deemed to be acting in concert with Celltech. Shareholders in OGS who wish to accept the Offer, and who have not yet done so, should return their Form(s) of Acceptance as soon as possible. Further Forms of Acceptance can be obtained from Lloyds TSB Registrars, The Causeway, Worthing, West Sussex BN99 6DA or by telephoning the Helpline on 0870 600 0673 (if calling from the United Kingdom), (1) 800 858 1202 (if calling from the United States or if you are an OGS ADS Holder) or +44 (0) 1903 702 767 (if calling from elsewhere). If you are an OGS ADS Holder and wish to accept the Offer, you should follow the instructions set out in the Letter of Transmittal. If OGS Shareholders or OGS ADS Holders are in any doubt as to the procedures for acceptance, they should contact the Helpline on the above numbers. A further announcement will be made in due course. Source: Evaluate™

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oxford Glycosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Glycosciences is included in 1 Expert Collection, including Omics.

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Oxford Glycosciences Patents

Oxford Glycosciences has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/9/2003

2/2/2010

Vaccines, G protein coupled receptors, Vaccination, Transcription factors, Cell signaling

Grant

Application Date

4/9/2003

Grant Date

2/2/2010

Title

Related Topics

Vaccines, G protein coupled receptors, Vaccination, Transcription factors, Cell signaling

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.